Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
126.20    -0.40 (-0.32%)
Bid:
125.20
Ask:
125.80
Spread: 0.60 (0.479%)
Market Cap: £307.19m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Form 8.5 (EPT/RI)

10 Oct 2022 09:18

RNS Number : 3204C
Liberum Capital Limited
10 October 2022
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PureTech Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

PureTech Health plc

(d) Date dealing undertaken:

07th October 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 25p

 

 

Purchase

 

14,664

 

2.21

 

2.2

 

ORD 25p

 

 

Sale

 

14,664

 

2.21

 

2.2

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

10th October 2022

 

Contact name:

Kristina Kapur

Telephone number:

020 3100 2034

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIBDGLBBDGDG
Date   Source Headline
18th Aug 20257:00 amRNSNotice of Results
13th Aug 20255:12 pmRNS-RPRTC's Vedanta Announces VE202 Phase 2 Results
12th Aug 202512:00 pmRNS-RPRTC Launches Celea to Advance Ph3-Ready IPF Drug
5th Aug 20255:30 pmRNSHolding(s) in Company
1st Aug 20257:00 amRNSTotal Voting Rights
17th Jul 202512:05 pmRNS-RPRTC’s Seaport Begins Phase 2b Study in MDD
16th Jul 20257:00 amRNSPureTech Announces Leadership Transition
8th Jul 20255:45 pmRNSDirectorate Change
4th Jul 20255:30 pmRNSPDMR Notification
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20257:00 amRNS-RPRTC'S Vor Announces RemeGen License & $175M PIPE
16th Jun 20255:27 pmRNSResult of AGM
29th May 20255:30 pmRNSHolding(s) in Company
22nd May 202512:00 pmRNS-RPRTC to Present at Jefferies Healthcare Conference
21st May 20257:00 amRNS-RPRTC: IPF Data Support Lung Function Stabilization
9th May 202512:00 pmRNS-RPRTC Publishes Research on Unmet IPF Patient Needs
1st May 202512:00 pmRNS-RPRTC To Present Ph2b IPF Results at ATS Conference
30th Apr 20257:00 amRNSFinal Results
23rd Apr 20257:00 amRNSNotice of Results
11th Apr 20257:00 amRNSHolding(s) in Company
9th Apr 20253:00 pmRNSForm 8.3 PURETECH HEALTH PLC
9th Apr 20257:00 amRNS-RPRTC Appoints Peel Hunt Joint UK Corporate Broker
8th Apr 20252:53 pmGNWInvesco Ltd: Form 8.3 - PureTech Health PLC; Opening Position disclosure
8th Apr 20252:48 pmEQSForm 8.3 - The Vanguard Group, Inc.: PureTech Health plc
8th Apr 20251:15 pmRNSForm 8.3 -PURETECH HEALTH PLC
8th Apr 20251:10 pmRNSForm 8.3 PURETECH HEALTH PLC
8th Apr 202511:40 amGNWForm 8.3 - [PURETECH HEALTH PLC - Opening Disclosure - 07 04 2025] - (CGAML)
8th Apr 202510:00 amRNSForm 8.3 - Puretech Health plc
7th Apr 20255:22 pmRNSRule 2.8 Announcement
7th Apr 20254:27 pmRNSStatement re Possible Offer
11th Mar 202511:05 amRNS-RPRTC's Seaport Adds Finance/Operations Exec to BOD
3rd Mar 20257:00 amRNSTotal Voting Rights
27th Feb 20255:30 pmRNSPDMR Notification RSU Vesting
25th Feb 202512:00 pmRNS-RPRTC Presents at Leerink Partners Healthcare Conf
12th Feb 202512:05 pmRNS-RPRTC's Seaport Publishes New Glyph Platform Data
27th Jan 20257:00 amRNS-RPRTC's Vedanta Publishes Ph2 in Nature Medicine
8th Jan 202512:00 pmRNS-RPureTech to Present at the JP Morgan Conference
6th Jan 20257:00 amRNS-RPureTech Appoints UBS as UK Corporate Broker
16th Dec 20247:00 amRNSPRTC's Ph2b in IPF Successful; New SOC Potential
11th Dec 20245:30 pmRNSHolding(s) in Company
27th Nov 20245:31 pmRNSHolding(s) in Company
27th Nov 20245:30 pmRNSHolding(s) in Company
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 20245:00 pmRNSDirector/PDMR Shareholding
21st Oct 20247:00 amRNSPRTC's Seaport Closes $225M Series B Financing
27th Sep 20247:00 amRNSKarXT/Cobenfy Approved by FDA; PRTC Receives $29M
6th Sep 20246:13 pmRNSHolding(s) in Company
28th Aug 20247:01 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.